PB018 not checked

Polpharma Biologics International AG

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Multiple Sclerosis
Main trialPhase 1
“This is a randomized, parallel group, double-blind, active-controlled, clinical pharmacology study to compare Pharmacokinetics, Pharmacodynamics and safety of PB018 versus Ocrevus in patients with Multiple Sclerosis.”In the company’s words, NCT07606521 on ClinicalTrials.gov
Copy of
Ocrevus (Genentech Inc)Tested side by side with the original in NCT07606521

Other drugs for Multiple Sclerosis

All 54 drugs for Multiple Sclerosis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting Dec 2027 A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow PB018

Following is part of Solo: you see every change to PB018 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in